Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06991114 | AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases. | PHASE2 | RECRUITING | 90 | — | — | Jul 9, 2025 | Jan 1, 2029 | May 22, 2026 | 52 | United States, Brazil +9 |
Dose Limiting toxicities assessed in a incrementing dose design.
| Arm | Type | Description |
|---|---|---|
| AlloNK | EXPERIMENTAL | AlloNK, dosed after a conditioning regimen, combined with Rituximab. |
| Name | Type | Description |
|---|---|---|
| Allogeneic NK Cells | DRUG | AlloNK, dosed after a conditioning regimen, combined with Rituximab. |
For Subjects with Refractory Rheumatoid Arthritis (RA): * Documented diagnosis of RA, meeting the 2010 ACR/EULAR classification criteria. * Rheumatoid Factor (RF) or Anti Citrullinated Protein Antibody (ACPA) positive. * High-sensitivity C-reactive protein (hs-CRP) \> 3 mg/L or Erythrocyte Sediment...